Document is current
Any future updates will be listed below
-
Authors
Wang, Zhiyong https://orcid.org/0000-0002-3574-6078
Wu, Victoria H.
Allevato, Michael M.
Gilardi, Mara
He, Yudou https://orcid.org/0000-0001-8733-8781
Luis Callejas-Valera, Juan https://orcid.org/0000-0002-5614-6370
Vitale-Cross, Lynn
Martin, Daniel
Amornphimoltham, Panomwat
Mcdermott, James
Yung, Bryan S.
Goto, Yusuke
Molinolo, Alfredo A.
Sharabi, Andrew B.
Cohen, Ezra E. W.
Chen, Qianming
Lyons, J. Guy https://orcid.org/0000-0002-4835-4663
Alexandrov, Ludmil B. https://orcid.org/0000-0003-3596-4515
Gutkind, J. Silvio https://orcid.org/0000-0002-5150-4482
- License Information
-
More Information
Article History
Received: 24 May 2019
Accepted: 8 November 2019
First Online: 5 December 2019
Competing interests
: J.S.G. has received other commercial research support from Kura Oncology and Mavupharma, and is a consultant/advisory board member for Oncoceuitics Inc., Vividion Therapeutics, and Domain Therapeutics; E.E.W.C. is a consultant/advisory board member for Merck, Bristol-Myers Squibb, AstraZeneca, Celgene, MSD, and Pfizer. A.B.S. is founder/CEO of Toragen, Inc., has received commercial research grants from Varian Medical Systems and Pfizer, speakers bureau honoraria from AstraZeneca, Varian Medical Systems, and Merck, holds ownership interest (including patents) in Toragen, Inc., and is a consultant/advisory board member for AstraZeneca. No potential conflicts of interest were disclosed by other authors.
